Saturday 17 October 2026
Export CRDL’s income statement to Excel — free account
Cardiol Therapeutics Inc.
CRDL Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS grew 42.9%, free cash flow grew 10.6% and total debt fell 38.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.10
0.05
−4.35%
Follow CRDL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | — | — | — | — |
P/S ratio |
— | — | — | — | 0.00 | — | — | — | — |
Altman Z-Score |
— | — | — | — | 3.42 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 6.47 | — | — | — | — |
P/FCF ratio |
— | — | — | — | 0.00 | — | — | — | — |
P/Operating CF |
— | — | — | — | (33.35) | — | — | — | — |
P/B ratio |
— | — | — | — | 1.75 | — | — | — | — |
Price to Tangible BV |
— | — | — | — | 1.76 | — | — | — | — |
EV/Sales |
— | — | — | — | 0.00 | — | — | — | — |
EV/EBITDA |
— | — | — | — | 0.00 | — | — | — | — |
EV/Operating CF |
— | — | — | — | (1.62) | — | — | — | — |
EV/FCF |
— | — | — | — | (1.62) | — | — | — | — |
Quick Ratio |
3.83 | 4.41 | 4.24 | 6.11 | 7.29 | 5.66 | 11.42 | 8.03 | 13.91 |
Current Ratio |
4.16 | 4.52 | 4.36 | 6.27 | 7.53 | 5.94 | 20.81 | 11.22 | 14.06 |
Net Debt/EBITDA |
0.62 | 0.76 | 1.18 | 1.45 | 2.18 | 0.68 | 0.48 | 2.35 | 1.44 |
Debt/Assets |
0.37% | 0.39% | 0.43% | 0.04% | 0.08% | 0.99% | 1.23% | 1.09% | 0.00% |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.05 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.71 | 0.68 | 0.90 | 0.88 | 0.74 | 0.45 | 0.83 | 0.69 | 0.78 |
Capex/Depreciation |
(0.24) | (0.06) | (0.26) | (0.34) | (0.06) | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | — | — | — | (540.22) | (114.86) | (18.51) | (47.84) |
| (156.96%) | (137.37%) | (68.23%) | (47.12%) | (70.83%) | (149.55%) | (76.10%) | (125.25%) | (14.24%) | |
| (120.54%) | (106.13%) | (55.64%) | (40.38%) | (61.10%) | (133.00%) | (70.00%) | (128.77%) | (12.82%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(188.25%) | (147.57%) | (99.76%) | (59.56%) | (41.67%) | (159.87%) | (95.93%) | (72.54%) | (71.38%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 1,887.77 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 13,811.31% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 35,414.01% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.03 | 0.04 | 0.03 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 10,796.82% | — | — | — | — |
Graham Net Nets |
— | — | — | — | 0.56 | — | — | — | — |
Graham Number |
— | — | — | — | 0.00 | — | — | — | — |
Earnings Yield |
— | — | — | — | (32.59%) | — | — | — | — |
Free Cash Flow Yield |
— | — | — | — | (23.09%) | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.20) | (0.26) | (0.29) | (0.33) | (0.43) | (0.24) | (0.34) | (0.52) | (0.04) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.20) | (0.26) | (0.29) | (0.34) | (0.43) | (0.24) | (0.34) | (0.52) | (0.04) |
Cash per Share |
0.18 | 0.31 | 0.40 | 0.73 | 1.55 | 0.37 | 0.21 | 0.80 | 0.08 |
Shareholders Equity per Share |
0.15 | 0.25 | 0.32 | 0.64 | 1.41 | 0.35 | 0.44 | 1.07 | 0.10 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.15 | 0.25 | 0.32 | 0.64 | 1.41 | 0.35 | 0.44 | 1.07 | 0.10 |
Free Cash Flow |
(17.09) | (18.30) | (18.70) | (21.00) | (18.80) | (7.23) | (8.75) | (8.01) | (1.03) |
Working Capital |
12.77 | 18.00 | 20.64 | 39.72 | 60.30 | 9.79 | 10.52 | 16.09 | 1.85 |
Capital Expenditures |
(0.02) | (0.02) | (0.05) | (0.06) | (0.01) | (0.03) | (0.33) | (0.01) | (0.02) |
Net Current Asset Value |
12.71 | 17.90 | 20.52 | 39.70 | 60.24 | 9.71 | 10.42 | 15.89 | 1.69 |
EV/EBIT |
— | — | — | — | 0.00 | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.16 | — | — | — | — |
Price to Operating Income |
— | — | — | — | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.86 | 1.91 | 0.74 | 0.74 | 0.62 | 0.48 | 0.26 | 3.57 | 2.84 |
Cash ROIC |
(60.64%) | (45.25%) | (39.86%) | (24.44%) | (14.71%) | (33.46%) | (52.16%) | (27.74%) | (24.15%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | 0.41 | 0.26 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | 28.63 | 2,711.32 | 0.00 | 0.00 |
Average Receivables |
0.21 | 0.24 | 0.29 | 0.35 | 0.25 | 0.44 | 0.53 | 0.21 | 0.21 |
Average Payables |
3.79 | 5.52 | 6.57 | 5.53 | — | — | — | — | — |
Average Inventory |
— | — | — | — | — | 0.44 | 0.44 | — | — |
Average Assets |
20.08 | 25.22 | 37.45 | 58.91 | 41.32 | 12.22 | 15.04 | 9.08 | 10.36 |
Average Common Equity |
15.42 | 19.49 | 30.54 | 50.49 | 35.64 | 10.87 | 13.83 | 9.33 | 9.33 |
Columns are period end dates